JP2019516768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516768A5 JP2019516768A5 JP2018561725A JP2018561725A JP2019516768A5 JP 2019516768 A5 JP2019516768 A5 JP 2019516768A5 JP 2018561725 A JP2018561725 A JP 2018561725A JP 2018561725 A JP2018561725 A JP 2018561725A JP 2019516768 A5 JP2019516768 A5 JP 2019516768A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- immune checkpoint
- ctl
- cancer
- apc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 21
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 20
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 19
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 19
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 19
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 13
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 13
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 8
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 8
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 8
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 8
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 8
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102000017578 LAG3 Human genes 0.000 claims description 7
- 101150030213 Lag3 gene Proteins 0.000 claims description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 229960003301 nivolumab Drugs 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 5
- 101710185679 CD276 antigen Proteins 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 5
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 5
- 102000002698 KIR Receptors Human genes 0.000 claims description 5
- 108010043610 KIR Receptors Proteins 0.000 claims description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 5
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 5
- 108091008874 T cell receptors Proteins 0.000 claims description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 5
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 229960002621 pembrolizumab Drugs 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 4
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- YQYGGOPUTPQHAY-KIQLFZLRSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccccc1)NC(=O)C(CCCCNN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)[C@H](C)O)C(C)C)[C@H](C)O YQYGGOPUTPQHAY-KIQLFZLRSA-N 0.000 claims description 3
- 101150059079 EBNA1 gene Proteins 0.000 claims description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 3
- 101150113776 LMP1 gene Proteins 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 2
- -1 PD -L1 Proteins 0.000 claims 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341402P | 2016-05-25 | 2016-05-25 | |
| US62/341,402 | 2016-05-25 | ||
| PCT/IB2017/000740 WO2017203362A1 (en) | 2016-05-25 | 2017-05-25 | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516768A JP2019516768A (ja) | 2019-06-20 |
| JP2019516768A5 true JP2019516768A5 (ru) | 2020-07-02 |
Family
ID=60411124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561725A Withdrawn JP2019516768A (ja) | 2016-05-25 | 2017-05-25 | がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3463398A4 (ru) |
| JP (1) | JP2019516768A (ru) |
| KR (1) | KR20190028664A (ru) |
| CN (1) | CN109496155A (ru) |
| AR (1) | AR108624A1 (ru) |
| AU (1) | AU2017271128A1 (ru) |
| CA (1) | CA3023845A1 (ru) |
| SG (1) | SG11201809541UA (ru) |
| WO (1) | WO2017203362A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7364237B2 (ja) * | 2017-08-10 | 2023-10-18 | グッド ティー セルズ、 インコーポレイテッド | 癌治療のためのｔ細胞の活性化方法 |
| WO2020227279A1 (en) * | 2019-05-06 | 2020-11-12 | Hasumi International Research Foundation | Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
| CN110452870A (zh) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品 |
| EP4048780A4 (en) * | 2019-10-23 | 2024-03-13 | Council Queensland Inst Medical Res | ADOPTIVE IMMUNOTHERAPY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002258941A1 (en) * | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| JP5623747B2 (ja) * | 2006-12-27 | 2014-11-12 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための組成物および方法 |
| WO2010065959A1 (en) * | 2008-12-05 | 2010-06-10 | Northeastern University | Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy |
| WO2013088114A1 (en) * | 2011-12-12 | 2013-06-20 | Cell Medica Limited | Process of expanding t cells |
| EP2892558B1 (en) * | 2012-09-07 | 2019-04-10 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
| WO2015157636A1 (en) * | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| KR20170078619A (ko) * | 2014-09-17 | 2017-07-07 | 더 존스 홉킨스 유니버시티 | 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법 |
| SG10201903912XA (en) * | 2014-10-31 | 2019-05-30 | Massachusetts Inst Technology | Delivery of biomolecules to immune cells |
-
2017
- 2017-05-25 JP JP2018561725A patent/JP2019516768A/ja not_active Withdrawn
- 2017-05-25 SG SG11201809541UA patent/SG11201809541UA/en unknown
- 2017-05-25 EP EP17802270.3A patent/EP3463398A4/en not_active Withdrawn
- 2017-05-25 WO PCT/IB2017/000740 patent/WO2017203362A1/en unknown
- 2017-05-25 AU AU2017271128A patent/AU2017271128A1/en not_active Abandoned
- 2017-05-25 KR KR1020187037498A patent/KR20190028664A/ko unknown
- 2017-05-25 CN CN201780045909.0A patent/CN109496155A/zh active Pending
- 2017-05-25 CA CA3023845A patent/CA3023845A1/en not_active Abandoned
- 2017-05-26 AR ARP170101457A patent/AR108624A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khan et al. | Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy | |
| Vijayakumar et al. | Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines | |
| ES2894257T3 (es) | Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados | |
| JP2019516768A5 (ru) | ||
| Cabo et al. | Trial watch: immunostimulatory monoclonal antibodies for oncological indications | |
| Duperret et al. | Synergy of immune checkpoint blockade with a novel synthetic consensus DNA vaccine targeting TERT | |
| JP7454645B2 (ja) | Ｈｉｖワクチン並びにその作製方法及び使用方法 | |
| CN115697387A (zh) | 抗bcma嵌合抗原受体的用途 | |
| Li et al. | Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma | |
| Catani et al. | Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma | |
| Liu et al. | Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect | |
| WO2019147925A1 (en) | Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy | |
| Tenesaca et al. | Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors | |
| JP2019520332A5 (ru) | ||
| AR108624A1 (es) | Combinaciones terapéuticas para el tratamiento del cáncer | |
| US20230248814A1 (en) | Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes | |
| JP2024514707A (ja) | 免疫療法における使用のための組成物及び方法 | |
| Seah et al. | Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response | |
| Neerincx et al. | Antibody-mediated delivery of TAPBPR enables the redirection of virus-specific T cell responses to tumour cells | |
| US20220088162A1 (en) | Heterologous Prime Boost Vaccine | |
| Lim et al. | Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance | |
| Dlamini et al. | Current immunotherapeutic treatments in colon cancer | |
| Cho et al. | Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus | |
| JP2024517131A (ja) | 免疫療法における使用のための組成物及び方法 | |
| CN116847882A (zh) | Hiv疫苗及其使用方法 |